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Cytomegalovirus (CMV) is a common opportunistic pathogen in 
immunocompromised individuals, including those infected with 
HIV, transplant recipients and patients using immunosuppressive 
agents. South Africa (SA) has an extremely high seroprevalence of 
CMV, with positive antibodies detected in 100% of HIV-infected 
individuals in rural primary care clinics.[1] Like all herpesviruses, 
CMV may remain latent after primary infection. Reactivation of 
CMV replication may not result in CMV disease in the host, and the 
diagnosis of CMV disease therefore poses a challenge to clinicians.[2] 
A wide spectrum of disease exists: a ‘CMV syndrome’ may occur 
(characterised by fever, myalgia, atypical lymphocytosis and 
thrombocytopenia), or the disease may be localised to specific organ 
sites.[3] The most common sites involve the ocular, gastrointestinal, 
lower respiratory tract and neurological systems. Involvement of the 
larynx is extremely rare. We present a rare case of tissue-invasive 
CMV disease of the supraglottic larynx presenting as a mass lesion 
that obstructed the respiratory tract.
Case report
A 33-year-old woman presented with type 1 respiratory failure, 
acute renal failure and diarrhoea. She had a background of 
seropositive rheumatoid arthritis, for which she had been taking 
20 mg prednisone daily for 2 years. She also had a history of using 
inhaled methamphetamine for several years, with the latest episode 
1 week prior to admission. On examination, she was cushingoid in 
appearance and was in significant respiratory distress. Bronchial 
breathing and crackles were apparent bilaterally.
Arterial blood gas measurement on admission revealed the patient 
to be in type 1 respiratory failure with a partial pressure of oxygen 
of 42.4 mmHg (5.6 kPa) and a partial pressure of carbon dioxide of 
23.1 mmHg (3 kPa). Baseline laboratory investigations revealed a 
serum creatinine level of 1 709 µmol/l with an estimated glomerular 
filtration rate of 2 mL/min/1.73 m2. She had a normocytic anaemia 
(haemoglobin 7.1 g/dL). Testing for perinuclear anti-neutrophil 
cytoplasmic antibodies (p-ANCA) was strongly positive (29 U/mL). 
Further results are set out in Table 1. High-resolution computed 
tomography of her chest showed bilateral lobular areas of air space 
opacification, sparing the periphery, with associated pleural effusions 
and septal thickening. Ceftriaxone and azithromycin were initiated as 
empirical cover for possible bacterial pneumonia.
The patient was intubated and admitted to the intensive care 
unit (ICU), and acute haemodialysis was commenced. A diagnosis 
of methamphetamine-induced glomerulonephritis was entertained. 
After 11 days she was extubated, and then received a short course 
of potent immunosuppressive therapy including a 600 mg dose of 
cyclosporine, three pulses of 500 mg methylprednisolone and three 
sessions of plasma exchange, after which she declined further plasma 
exchange sessions. Three days after the cyclosporine, she developed 
grade 4 stridor and was urgently reintubated. Direct laryngoscopy 
unexpectedly revealed a supraglottic mass (Fig. 1).
A tracheostomy was performed and a biopsy specimen of the 
mass was taken and submitted for histopathological examination. 
Haematoxylin and eosin (H&E) sections revealed mucosal ulceration 
with underlying inflamed granulation tissue and associated viral 
cytopathy in keeping with florid CMV infection, with enlarged cells 
and nucleomegaly (Fig. 2).  Occasional basophilic intranuclear bodies 
and granular intracytoplasmic inclusions were also seen. In addition, 
CMV immunohistochemical staining of cells was positive (Fig. 3A 
and B). There were no signs of dysplasia or malignancy. A serum 
CMV viral load of 460 IU/mL was noted at treatment initiation. 
Serological markers were representative of latent infection with a 
positive IgG and negative IgM.
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A 33-year-old woman on chronic immunosuppressive treatment for rheumatoid arthritis with a history of inhaled methamphetamine 
use presented with respiratory failure requiring mechanical ventilation for a prolonged period. After being given plasma exchange, pulses 
of methylprednisolone and a dose of cyclosporine for suspected ANCA (anti-neutrophilic cytoplasmic autoantibodies) vasculitis, she 
developed an obstructive supraglottic laryngeal mass that required a tracheostomy to bypass. Biopsy findings revealed the mass to be an 
inflammatory pseudomass secondary to cytomegalovirus (CMV). The mass resolved after several weeks of intravenous ganciclovir therapy. 
This is an extremely unusual presentation of localised CMV disease, with only two or three similar cases having been reported worldwide.
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Case management
Intravenous (IV) ganciclovir at a renally adjusted dose of 100 mg 
was commenced on alternate days after haemodialysis sessions. The 
patient was transferred to a high-care area. CMV viral loads were 
monitored weekly and ganciclovir was continued until CMV plasma 
viral loads were undetectable by highly sensitive assay 3 weeks later. 
Two weeks after the initiation of therapy, repeat imaging by video 
laryngoscopy showed near-complete resolution of the mass. However, 
the tracheostomy tube was not removed owing to the development of 




White cell count (× 109/L) 11.48 3.9 - 12.6
Haemoglobin (g/dL) 7.1 11.6 - 16.4
MCV (fL) 81.4 78.9 - 98.5
Platelet count (× 109/L) 356 186 - 454
Neutrophils (× 109/L (%)) 10.05 (92.5) 1.6 - 8.30
Lymphocytes (× 109/L (%)) 0.87 (8.0) 1.4 - 4.5
Sodium (mmol/L) 127 136 - 145
Potassium (mmol/L) 7.4 3.5 - 5.1
Chloride (mmol/L) 96 98 - 107
Bicarbonate (mmol/L) 10 23 - 29
Urea (mmol/L) 48.3 2.1 - 7.1
Creatinine (µmol/L) 1 709 49 - 90
HIV ELISA Negative -
Anti-CCP antibody (U/mL) Positive (646.0) -




Rheumatoid factor (IU/mL) 573 -
Arterial blood gas
pH 7.287 7.35 - 7.45
PCO2 (mmHg) 23.1 35 - 45
PO2 (mmHg) 42.4 >60
Sodium (mmol/L) 123 136 - 145
Potassium (mmol/L) 7 3.5 - 5
Chloride (mmol/L) 106 98 - 107
Glucose (mmol/L) 5.6 >4.0
Lactate (mmol/L) 0.9 <1.5
HCO3 (mmol/L) 12.8 24 - 26
BE (mmol/L) –14.5 –2 - +2
MCV =  mean cell volume; ELISA = enzyme-linked immunosorbent assay; CCP = cyclic 
citrullinated peptide; HCO3 = bicarbonate; BE = base excess.




 Fig. 2. Inflamed granulation tissue showing neovascularisation, mixed 
inflammation, reactive fibroblasts and an enlarged cell (arrow) showing 
evidence of CMV inclusions (H&E ×400). (CMV = cytomegalovirus; 
H&E = haematoxylin and eosin.)
Fig. 3. Strong nuclear staining, confirming the presence of CMV 
infection within the ulcer bed. A: CMV IHC ×100; B: CMV IHC ×400). 
(CMV = cytomegalovirus; IHC = immunohistochemistry.) 
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an anterior glottic web with a narrowed airway. Following discharge, 
readmissions occurred for episodes of intermittent haemoptysis and 
ongoing dialysis, thought to be related to the patient’s ANCA-positive 
vasculitis. However, there was no recurrence of the CMV mass. Three 
months after insertion, the tracheostomy tube remained in situ and 
the patient was awaiting renal replacement therapy in the form of 
peritoneal dialysis.
Discussion
CMV is part of the beta-herpesvirus subfamily.[4] After the 
establishment of latent disease, robust immunity prevents reinfection 
or reactivation. Primary infection in an immunocompetent host 
typically results in a mild viral syndrome or is subclinical.[3] However, 
in immunocompromised hosts, viral replication may reactivate and 
cause severe disease in various organs.[3]
The diagnosis of invasive disease is not straightforward, as viral 
replication can be subclinical, and the presence of CMV in the blood 
or in tissue therefore does not necessarily imply CMV disease.[3] 
Furthermore, particularly in the case of retinal or gastrointestinal 
involvement, severe disease may occur without significant viral 
replication being detected in the plasma.[5] In this case the extensive 
CMV-induced changes and positive immunohistochemistry in the 
tissue samples, as well as the absence of any other cause for the mass 
noted histopathologically, support our contention that the occluding 
supraglottic mass was purely caused by CMV. This case highlights 
the importance of prompt biopsy of lesions in immunocompromised 
patients.
In the literature, only a handful of case reports have documented 
specific laryngeal manifestations of CMV.[6-9] Some reports detail 
laryngeal ulceration, and to the best of our knowledge only two, 
possibly three, reports describe distinct mass-like lesions of the 
larynx caused by CMV. Tinelli et al.[6] described a young HIV-positive 
female patient with a CD4 count of 38 cells/µL who developed 
localised CMV disease with irregular growths of the posterior wall 
of the hypopharynx. The patient experienced clinical improvement 
after 3 weeks’ treatment with IV ganciclovir; however, she had some 
clinical recurrence of pharyngeal ulceration after 5 months while 
on a maintenance dose of 5 mg/kg 3 times a week. Subsequently 
the maintenance dose was adjusted to long-term daily doses of 
ganciclovir, with mild improvement of the ulceration. In another 
case report, Friedman et al.[7] described a patient with no evidence of 
immunocompromise who presented with airway obstruction caused 
by a pedunculated CMV subglottic mass. Surgical excision of the 
mass alone was curative, and there was no need to use ganciclovir.
Akimoto et al.[8] described a patient with nephrotic syndrome 
on steroids with concurrent active herpes zoster ophthalmicus who 
developed airway compromise caused by a supraglottic mass of the 
larynx, presumptively caused by herpes zoster and initially treated 
as such. Later blood tests revealed positive CMV antigenaemia, 
after which treatment was changed to IV ganciclovir. It is difficult to 
assess the cause of the mass, as no histological diagnosis was proven. 
Despite this, the mass had resolved after 24 days of IV ganciclovir 
given 3 times a week.
In our case, the finding of a CMV-related laryngeal mass was 
unexpected. The patient’s risk factors included chronic use of low-
dose prednisone, a prolonged ICU stay that included mechanical 
ventilation, ANCA-positive vasculitis, a pulse of methylprednisolone 
and cyclosporine, and three sessions of plasma exchange.
In a prospective observational study, it was found that CMV 
reactivation was independently associated with an increased duration 
of ICU and hospital stay and with prolonged mechanical ventilation.[10] 
Additionally, other reviews have found that risk factors for opportunistic 
infection in ANCA-associated vasculitis include aggressiveness of 
induction therapy, cumulative exposure to steroids, older age and 
impairment of renal function, especially dialysis dependence, which 
are all relevant risks in our case (except for age).[11]
Another question to answer is why the CMV disease manifested so 
profoundly in the supraglottic larynx, a highly unusual site. Our patient 
had used inhaled methamphetamines for several years. This illicit 
drug promotes airway injury[12] and also has immune-modulating 
effects.[13] Some consequences include irritation of mucosa causing 
nonspecific inflammation, release of proinflammatory mediators, 
and oxidative stress.[14,15] Methamphetamines cause a dysregulated 
immune response.[13] Infrequent reports of respiratory complications 
have noted pulmonary hypertension, pulmonary oedema and 
barotrauma resulting from its inhalation.[12] In addition, the patient 
had recently been intubated. Some studies have postulated that 
mechanical abrasion may reactivate latent infection in endothelial 
cells, particularly those exposed to shear stress.[16,17]
The combination of tracheal intubation and inhaled 
methamphetamine use may explain why the patient’s CMV disease 
was so well localised, though this hypothesis is somewhat speculative. 
An additional consideration is that certain forms of p-ANCA-positive 
vasculitis, such as granulomatosis with polyangiitis, may affect the 
larynx, although there was no evidence of granuloma formation or 
necrotising vasculitis on the biopsy specimens.
Conclusions
CMV disease of the larynx is uncommon, and disease manifesting as 
a mass lesion that obstructs respiration even more so. Our patient’s 
extremely unusual presentation was probably due to a combination 
of CMV reactivation from profound immunosuppression together 
with tracheal abrasion and damage from her recent endotracheal 
intubation and possibly chronic inhaled methamphetamine use.
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